Skip directly to content

Pfizer Completes Acquisition of Nimenrix and Mencevax from GlaxoSmithKline


NEW YORK, N.Y., October 1 – Pfizer Inc. (NYSE: PFE) today announced that it has completed the acquisition of GlaxoSmithKline’s vaccines Nimenrix and Mencevax.
“The addition of Nimenrix and Mencevax help us to fulfill our vision to protect lives with innovative vaccines to fight serious diseases worldwide,” said Susan Silbermann, president and general manager, Pfizer Vaccines. “These vaccines add high-quality and complementary vaccines to our existing portfolio, allowing us to reach a broader global population.”
About Pfizer Inc.
At Pfizer, we apply science and our global resources to bring therapies to people that extend and significantly improve their lives.  We strive to set the standard for quality, safety and value in the discovery, development and manufacture of health care products.  Our global portfolio includes medicines and vaccines as well as many of the world's best-known consumer health care products.  Every day, Pfizer colleagues work across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases of our time.  Consistent with our responsibility as one of the world's premier innovative biopharmaceutical companies, we collaborate with health care providers, governments and local communities to support and expand access to reliable, affordable health care around the world.  For more than 150 years, Pfizer has worked to make a difference for all who rely on us.  To learn more, please visit us at
DISCLOSURE NOTICE: The information contained in this release is as of October 1, 2015. Pfizer assumes no obligation to update forward-looking statements contained in this release as the result of new information or future events or developments.

This release contains forward-looking information about the acquisition by Pfizer of GlaxoSmithKline’s vaccines, Nimenrix and Mencevax, and the potential benefits thereof, that involves substantial risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. Risks and uncertainties include, among other things, the ability to realize the anticipated benefits of the acquisition; other business effects, including the effects of industry, market, economic, political or regulatory conditions; future exchange or interest rates; the uncertainties inherent in research and development; whether and when regulatory authorities in jurisdictions in which applications are pending will approve such applications, which will depend on the assessment by such regulatory authorities of the benefit-risk profile suggested by the totality of the efficacy and safety information submitted; decisions by regulatory authorities regarding labeling and other matters that could affect the availability or commercial potential of the vaccines; and competitive developments.
A further description of risks and uncertainties can be found in Pfizer’s Annual Report on Form 10-K for the fiscal year ended December 31, 2014, including in the sections thereof captioned “Risk Factors” and “Forward-Looking Information and Factors That May Affect Future Results”, as well as in its subsequent reports on Form 10-Q and Form 8-K, all of which are filed with the SEC and available at and

Media Contact:
Joan Campion
+1.212.733.2798 (O)
+1.201.761.9384 (M)
Investor Contact:
Ryan Crowe
+1.212.733.8160 (O)
+ (M)